Inal M, Kanbak G, Sen S, Akyüz F, Sunal E
Department of Biochemistry, The Medical School, Osmangazi University, Eskişehir, Turkey.
Free Radic Res. 1999 Sep;31(3):211-6. doi: 10.1080/10715769900300771.
In this study, plasma and red blood cell (RBC) antioxidant status and plasma lipid peroxidation were investigated in 46 hemodialysis patients. In addition, the effect of erythropoietin (EPO) and EPO-vitamin E combination therapy on plasma and RBC antioxidant status, and plasma lipid peroxidation were examined. There were 10 healthy subjects in the control group and 10 hemodialysis patients in the untreated group. The third group included 36 hemodialysis patients that were given EPO (100 U/kg) for 3 months, 3 times per week. The fourth group included 36 hemodialysis-patients from the EPO group that were given EPO at a 50% decreased dose + vitamin E (300 mg/day) for 3 months. MDA levels in the untreated group, the EPO group and the EPO + vitamin E groups were found to be higher than the control group (p < 0.001, in both). Furthermore, MDA levels in both of the treatment groups were lower when compared to the untreated group (p < 0.001, in both). Plasma vitamin E levels in the untreated, the EPO group and EPO + vitamin E groups were lower than the control group (p < 0. 001). In contrast, plasma vitamin E levels in the treatment groups were higher in comparison with the control group (p < 0.05). SOD activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001). SOD activities in the treatment groups were higher than the control group (p<0.001). The SOD activities in the EPO+vitamin E group increased when compared to the EPO group (p < 0.001). CAT activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001 in untreated and EPO groups, p <0.01 in EPO+ vitamin E group). CAT activities in EPO and EPO+ vitamin E groups were increased when compared to the untreated group (p < 0.01). In conclusion, our findings have shown that antioxidant status decreased and lipid peroxidation increased in hemodialysis patients. EPO has an antioxidant effect on the RBC and plasma antioxidant status, and plasma lipid peroxidation. These effects were moderately increased by the combination of vitamin E and EPO.
在本研究中,对46例血液透析患者的血浆和红细胞(RBC)抗氧化状态以及血浆脂质过氧化情况进行了调查。此外,还研究了促红细胞生成素(EPO)和EPO-维生素E联合治疗对血浆和RBC抗氧化状态以及血浆脂质过氧化的影响。对照组有10名健康受试者,未治疗组有10名血液透析患者。第三组包括36例血液透析患者,每周接受3次EPO(100 U/kg)治疗,持续3个月。第四组包括36例来自EPO组的血液透析患者,给予剂量降低50%的EPO + 维生素E(300 mg/天),持续3个月。发现未治疗组、EPO组和EPO + 维生素E组的丙二醛(MDA)水平均高于对照组(两者均为p < 0.001)。此外,与未治疗组相比,两个治疗组的MDA水平均较低(两者均为p < 0.001)。未治疗组、EPO组和EPO + 维生素E组的血浆维生素E水平低于对照组(p < 0.001)。相比之下,治疗组的血浆维生素E水平高于对照组(p < 0.05)。发现未治疗组、EPO组和EPO + 维生素E组的超氧化物歧化酶(SOD)活性低于对照组(p < 0.001)。治疗组的SOD活性高于对照组(p<0.001)。与EPO组相比,EPO + 维生素E组的SOD活性增加(p < 0.001)。发现未治疗组、EPO组和EPO + 维生素E组的过氧化氢酶(CAT)活性低于对照组(未治疗组和EPO组为p < 0.001,EPO + 维生素E组为p <0.01)。与未治疗组相比,EPO组和EPO + 维生素E组的CAT活性增加(p < 0.01)。总之,我们的研究结果表明,血液透析患者的抗氧化状态降低,脂质过氧化增加。EPO对RBC和血浆抗氧化状态以及血浆脂质过氧化具有抗氧化作用。维生素E与EPO联合使用可适度增强这些作用。